Iovance Biotherapeutics, Inc. (IOVA) · Oct 29, 2026 · Other events
Above the bar — 59.1% ORR in enriched subgroup vs 24.6% across 69 patients
Iovance’s lung cancer results keep broad efficacy roughly unchanged but introduce a biomarker-selected subgroup that could reshape lifileucel development.
Iovance is a commercial-stage TIL company using Amtagvi revenue to fund expansion into additional solid tumors, including its ongoing non-small-cell lung cancer program; second-quarter Amtagvi revenue was $90.7 million, while IOV-LUN-202 remains a key potential growth application.
The broad lung-cancer signal did not materially improve. Adding 30 patients brought Cohorts 1 and 2 to 69, and the total response count implies a 24.6% ORR—essentially unchanged from the previously reported 25.6% in 39 patients. That makes the overall dataset more confirmatory than breakthrough. 〔0〕
| Metric | Current | Comparator |
|---|---|---|
| Overall ORR (IOV-LUN-202 results) | 24.6% (17/69) | 25.6% (39 patients, prior update) |
| KRAS wild-type ORR (Biomarker analysis) | 43.3% (13/30) | 11.4% KRAS-mutant |
| Enriched-subgroup ORR (Biomarker analysis) | 59.1% (13/22) | 31.9% of study population |
| Frontline Cohort 3A ORR (Frontline analysis) | 85.7% (6/7) | — |
The real news is the concentration of responses, not the headline cohort rate. Patients meeting the KRAS-wild-type, HER2-wild-type and current-or-former-smoking criteria represented less than one-third of the population but generated 13 of the 17 observed responses, including both complete responses. That is a potentially important development because it gives Iovance a way to turn an uneven retrospective result into a defined patient-selection strategy. 〔1〕
The strategy advances the program, but it is not yet validation. The 59.1% rate comes from only 22 retrospectively selected patients, and the company still needs prospective confirmation. POSITILITY is intended to provide that test, with enrollment starting in November 2026 across the existing IOV-LUN-202 network and a potential registrational path subject to FDA feedback. 〔2〕
The frontline data broaden the opportunity but add another early-stage bet. An 85.7% ORR in six of seven biomarker-aligned patients supports testing lifileucel with pembrolizumab without chemotherapy, but the sample is even smaller and HER2 status was not assessed. OPTILISM is planned for 2027, so this is strategic support rather than near-term clinical proof. 〔3〕
Bottom line: This update does not make the broad lung dataset stronger, but it gives Iovance a credible precision-development angle that could improve the odds of a focused registrational program. The value is in the prospective test now starting—not in treating the retrospective subgroup as established efficacy. 〔4〕
POSITILITY enrollment begins November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!